Topic: MS

Optimizing treatment of RRMS: Canadian recommendations

September 4, 2013  

Who prescribes DMTs for MS?

June 5, 2013  

Alemtuzumab: phase III results

April 10, 2013  

Disease activity-free rates at 1 and 2 years

March 23, 2013  

Second-line switching: three reports

March 23, 2013  

CCSVI: has the balloon burst?

March 23, 2013  

BG-12: two analyses of safety results

March 22, 2013  

Natalizumab update: anti-JCV Ab testing and PML risk

March 22, 2013  

Brain atrophy reduced with fingolimod

March 22, 2013  

Pregnancies may slow disability progression

March 21, 2013